US patent No. 8,642,564 provides methods for oral delivery of nucleotide-oligomer analogs including anti-sense and RNA interference drugs. Such drugs represent an important new class of therapeutics but are generally poorly absorbed in the GI tract and thus must be administered by injection.
Oral delivery provides greater patient convenience and acceptance as well as reduced administration costs and greater flexibility in dosing schedules to allow for maximum therapeutic efficacy.
Aegis licenses its Intravail drug delivery and ProTek protein stabilization technologies to biopharmaceutical companies worldwide.